Phosphodiesterases 5 Inhibitors and Erectile Dysfunction Recovery after Pelvic Surgery: Future Perspectives for New Drugs and New Formulations
- 31 December 2020
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 22 (1) , 31-37
Abstract
Background: Phosphodiesterase 5 inhibitors (PDE5I) represent the first line treatment in the management of post-operative erectile dysfunction (ED) after pelvic oncological surgery. Aim of our study is to evaluate the available evidence on the efficacy of PDE5Is including new formulations and penile rehabilitation post-pelvic surgery. Evidence Acquisition: A systematic review of the literature was performed until May 2020. The following databases were searched: Scopus, Medline and Web of Science. The MeSH search was conducted by combining the following terms: ‘erectile dysfunction’, ‘radical prostatectomy’ ‘pelvic’ ‘bladder’ ‘phosphodiesterase’ inhibitors’ ‘avanafil’ ‘sildenafil’ ‘tadalafil’ ’lodenafil’ ‘mirodenafil’ ‘udenafil’ ‘vardenafil’ ‘sublingual’ ‘orodispersible’ ‘penile’ ‘rehabilitation’. PRISMA guidelines were followed to select relevant papers (figure 1). Evidence Synthesis: Sildenafil, Tadalafil, vardenafil and Avanafil improves EF compared with placebo in men with all levels of ED severity after radical prostatectomy with good tolerability. No specific recommendations can be suggested regarding the superiority of a drug over the other. The optimal dose, continuous vs on demand and duration of treatment is still under investigation. In vitro and preclinical studies suggest a possible role for lodenafil, mirodenafil and oro-dispersible formulations in patients undergoing oncological pelvic surgery. Few studies demonstrated the efficacy of udenafil in improving ED after rectal surgery or radical prostatectomy. Complete recovery of EF after surgery is still an unmet need in the field of penile rehabilitation after pelvic surgery. Conclusion: PDE5I have a crucial role in the management of post pelvic surgery ED. New drugs and new formulations have shown excellent results in patients with ED, however data in patients after surgery is still scarce. Further well designed RCT should clarify the role of these new compounds and oro-dispersible formulations in the management of ED in patients undergoing pelvic surgery.Keywords
This publication has 27 references indexed in Scilit:
- Nightly vs on‐demand sildenafil for penile rehabilitation after minimally invasive nerve‐sparing radical prostatectomy: results of a randomized double‐blind trial with placeboBJU International, 2013
- A Phase 3, Placebo Controlled Study of the Safety and Efficacy of Avanafil for the Treatment of Erectile Dysfunction After Nerve Sparing Radical ProstatectomyJournal of Urology, 2013
- Systematic Review and Meta-analysis of Studies Reporting Potency Rates After Robot-assisted Radical ProstatectomyEuropean Urology, 2012
- Efficacy and Safety of an Orodispersible Vardenafil Formulation for the Treatment of Erectile Dysfunction in Elderly Men and Those with Underlying Conditions: An Integrated Analysis of Two Pivotal TrialsThe Journal of Sexual Medicine, 2011
- ORIGINAL RESEARCH—ED PHARMACOTHERAPY: Efficacy and Tolerability of Lodenafil Carbonate for Oral Therapy of Erectile Dysfunction: A Phase III Clinical TrialThe Journal of Sexual Medicine, 2010
- Efficacy and Tolerability of Lodenafil Carbonate for Oral Therapy in Erectile Dysfunction: A Phase II Clinical TrialThe Journal of Sexual Medicine, 2009
- Pharmacological characterization of a novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosumEuropean Journal of Pharmacology, 2008
- Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomyInternational Journal Of Impotence Research, 2008
- The Use of an Erectogenic Pharmacotherapy Regimen Following Radical Prostatectomy Improves Recovery of Spontaneous Erectile FunctionThe Journal of Sexual Medicine, 2005
- Sildenafil Preserves Intracorporeal Smooth Muscle After Radical Retropubic ProstatectomyJournal of Urology, 2004